Loading...

    Explore
    • Policy Monitoring
    • Live Policy Feed
    • Billing Codes
    • Healthcare Providers
    • Health Insurance Payers
    • States
    • Service Lines
    • Taxonomy Codes
    Lookup tools
    • Billing Code Lookup
    • CPT Modifier Lookup
    • Provider Taxonomy Code Lookup
    • Healthcare Provider & Facility Lookup
    • Health Insurance Payer Lookup
    • Payer Contact Directory

    Policy & Benchmark Tools

    • Prior Authorization Lookup
    • Coverage Criteria Lookup
    • Timely Filing Lookup
    • Billing Code Reimbursement Rates
    • Payer Comparison Dashboard
    • Facility Comparison Dashboard
    • All tools

    Company

    • About OpenPayer
    • Data Sources
    • Request a Policy / Feedback
    • Trek Health
    OpenPayerby Trek Health
    LinkedInYouTube

    © 2026 Trek Health. All rights reserved.

    OpenPayer is built and maintained by Trek Health.

    v1.0.32
    OpenPayerPolicy UpdatesPharmacy & Specialty DrugsZing Health NSCLC Step Therapy Coverage | OpenPaye…
    Ask Trek AI about this page
    CurrentZing HealthPolicy 6305-D

    Medicare Part B Step Therapy PD1/PDL1 Products - Non-Small Cell Lung Cancer (NSCLC)

    Customize your policy alerts

    Sign up for zing_health Policy 6305-D alerts

    Get alerted when Policy 6305-D changes without checking for updates manually.

    Monitor payer policy activity

    Receive email alerts as soon as relevant payer policies are published or updated.

    This policy governs Medicare Part B coverage of specified PD-1/PD-L1 products for non-small cell lung cancer (NSCLC). Libtayo is preferred, while non-preferred products require prior authorization and an approved clinical exception for members new to non-preferred treatment.

    Policy Summary
    PayerZing Health
    PolicyMedicare Part B Step Therapy PD1/PDL1 Products - NSCLC
    Policy CodePolicy 6305-D
    Change TypeNo material change
    Effective DateN/A
    Next Review DateN/A
    Key ActionUse preferred Libtayo (cemiplimab) first unless the member qualifies for a clinical exception and obtains prior authorization for the non-preferred product.
    SourceLink
    POLICY UPDATE CHANGES

    No material clinical or coverage changes in this revision.

    1Preferred product
    4Non-preferred products
    365 daysPrior-use lookback
    7Coverage pathways

    OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.

    Non-Preferred Product Clinical Exceptions

    Non-preferred product clinical exceptions

    Coverage for a non-preferred product is provided when the member meets at least one of the following criteria.

    Non-preferred product exception criteria

    • Prior non-preferred treatment: The member has received treatment with the non-preferred product in the past 365 days.past 365 days
    • Intolerable adverse event: The member has had a documented intolerable adverse event to the preferred product.documented intolerable adverse event
    • Keytruda advanced or metastatic NSCLC: Keytruda is being used for advanced or metastatic NSCLC with adenocarcinoma or squamous cell histology and PD-L1 expression of greater than or equal to 1-49%.PD-L1 expression greater than or equal to 1-49%
    • Adjuvant NSCLC treatment: Keytruda, Imfinzi, or Tecentriq is being used for the adjuvant treatment of NSCLC.adjuvant treatment
    • Imfinzi after concurrent chemoradiation: Imfinzi is being used following concurrent chemoradiation for NSCLC.following concurrent chemoradiation
    • Neoadjuvant NSCLC treatment: Keytruda, Imfinzi, or Opdivo is being used for the neoadjuvant treatment of NSCLC.neoadjuvant treatment

    PD-L1 Expression

    PD-L1 Expression
    PD-L1 expressionGreater than or equal to 1-49%
    Applicable productKeytruda
    Treatment settingAdvanced or metastatic NSCLC with adenocarcinoma or squamous cell histology

    Prior Authorization and Preferred Product Requirements

    Prior Authorization

    Prior Authorization and Exception Review

    Prior authorization is required for non-preferred products through the exception process. Preferred products may also require a clinical prior authorization review, in addition to applicable Medicare Part B coverage and utilization-management requirements.

    • Non-preferred products: Imfinzi (durvalumab), Keytruda (pembrolizumab), Opdivo (nivolumab), and Tecentriq (atezolizumab).
    • Coverage for a non-preferred product is considered when clinical circumstances exclude use of the preferred product or when the member has previously used the product.
    Step Therapy

    Preferred Product First

    Use the preferred product first for members who are new to treatment with a non-preferred product. Libtayo (cemiplimab) is the preferred PD-1/PD-L1 product; request an exception through prior authorization before initiating a non-preferred product unless an applicable exception criterion is documented.

    • Preferred product: Libtayo (cemiplimab).
    • The step-therapy requirement applies in addition to any applicable National Coverage Determination, Local Coverage Determination, and Medicare Part B utilization-management program.
    Documentation Required

    Documented Intolerance to Preferred Product

    To support an exception based on intolerance, document that the member experienced an intolerable adverse event to Libtayo (cemiplimab). The documentation should identify the adverse event and support that it was clinically intolerable.

    • Documented intolerance to the preferred product is an accepted exception basis.
    • Include relevant clinical details in the prior authorization submission.
    Denial Risk

    No Approved Exception, No Coverage

    Coverage for a non-preferred product may be denied when the member does not meet any listed exception criterion and no approved exception to the preferred-product step-therapy requirement applies.

    • Listed exceptions include prior treatment with the non-preferred product within the past 365 days; documented intolerable adverse event to Libtayo; specified Keytruda use for advanced or metastatic NSCLC with adenocarcinoma or squamous cell histology and PD-L1 expression of 1–49%; adjuvant treatment with Keytruda, Imfinzi, or Tecentriq; Imfinzi following concurrent chemoradiation; or neoadjuvant treatment with Keytruda, Imfinzi, or Opdivo.

    Policy Background

    This policy applies to Medicare Part B coverage of specified PD-1/PD-L1 immunotherapy products for non-small cell lung cancer (NSCLC). Coverage is differentiated by preferred-product status and treatment setting, including advanced or metastatic disease, adjuvant therapy, treatment following concurrent chemoradiation, and neoadjuvant therapy.

    Libtayo (cemiplimab) is the preferred product. Imfinzi (durvalumab), Keytruda (pembrolizumab), Opdivo (nivolumab), and Tecentriq (atezolizumab) are non-preferred products. Members new to treatment with a non-preferred product generally require prior authorization through the exception process; coverage may be approved when a listed clinical exception applies.

    Initial Non-Preferred Therapy

    Initial non-preferred therapy

    For a member new to treatment with a non-preferred product, coverage is provided when at least one clinical exception criterion is met.

    Initial non-preferred product exception

    • Prior use: The member received the requested non-preferred product within the past 365 days.past 365 days
    • Preferred-product intolerance: The member experienced a documented intolerable adverse event to Libtayo.documented intolerable adverse event
    • Specified NSCLC treatment setting: The requested product is being used in one of the policy-specified advanced or metastatic, adjuvant, post-concurrent-chemoradiation, or neoadjuvant NSCLC settings.see product-specific treatment settings

      Product-specific restrictions apply to Keytruda, Imfinzi, Tecentriq, and Opdivo as described in the policy.

    Preferred Product Step Therapy

    StepPreferred product requirementNon-preferred product coverage
    1Use Libtayo (cemiplimab) first.Covered only when the member meets at least one clinical exception criterion and obtains prior authorization through the exception process. Exceptions include prior use of the non-preferred product within the past 365 days, a documented intolerable adverse event to Libtayo, or a specified NSCLC treatment setting.
    Policy Summary
    PayerZing Health
    PolicyMedicare Part B Step Therapy PD1/PDL1 Products - NSCLC
    Policy CodePolicy 6305-D
    Change TypeNo material change
    Effective DateN/A
    Next Review DateN/A
    Key ActionUse preferred Libtayo (cemiplimab) first unless the member qualifies for a clinical exception and obtains prior authorization for the non-preferred product.
    SourceLink
    On This Page
    Non-Preferred Product Clinical ExceptionsPD-L1 ExpressionPrior Authorization and Preferred Product RequirementsPolicy BackgroundInitial Non-Preferred TherapyPreferred Product Step Therapy